Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 9, 2001, Pages 1323-1329

  Carty, E ^a   Rampton, D S ^a,e   Schneider, H ^b   Rutgeerts, P ^c   Wright, J P ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MILPARK HOSPITAL   (South Africa)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Kingsbury Hospital   (South Africa)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RIDOGREL; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ANUS FISSURE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; ENTERITIS; ERYTHEMA NODOSUM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; TREATMENT OUTCOME; VOMITING;

ADULT; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PATIENT DROPOUTS; PENTANOIC ACIDS; PYRIDINES; THROMBOXANE-A SYNTHASE; TREATMENT FAILURE;

EID: 0034840229     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01056.x     Document Type: Article

References (34)

1. Prostaglandins and ulcerative colitis
2. Inflammatory bowel disease: Etiology and pathogenesis
3. In vivo profiles of eicosanoids in ulcerative colitis. Crohn's colitis, and Clostridium difficile colitis
4. Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa
5. Review article: Thromboxanes in inflammatory bowel disease - Pathogenic and therapeutic implications
6. Imbalance of prostacyclin and thromboxane synthesis in Crohn's disease
7. Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease
8. Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory diseases of the bowel
9. Platelets as inflammatory cells
10. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event
11. Enhancement of granulocyte-endothelial cell adherence and granulocyte-induced cytotoxicity by platelet release products
12. Platelets circulate in an activated state in inflammatory bowel disease
13. Thromboembolism in inflammatory bowel disease: Role of platelets
14. Pathogenesis of Crohn's disease: Multifocal gastrointestinal infarction
15. Vascular complications of inflammatory bowel disease
16. Regulation of tumor necrosis factor-alpha and IL-1 beta synthesis by thromboxane A2 in nonadherent human monocytes
17. An inhibitor of thromboxane production attenuates tumor necrosis factor release by activated human alveolar macrophages
18. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
19. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease
20. R 68 070: Thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule - I. Biochemical profile in vitro
21. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis
22. Ridogrel for the treatment of mild to moderate ulcerative colitis
23. Ridogrel for the treatment of mild to moderate ulcerative colitis. A placebo controlled trial
24. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis
25. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study
26. A simple index of Crohn's disease activity
27. Statistics and ethics in medical research: III How large a sample?
28. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: Anti-inflammatory profile in inflammatory bowel disease
29. Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease
30. An open trial of antiplatelet therapy in active Crohn's disease using Picotamide, a thromboxane antagonist
31. Review article: Platelets in inflammatory bowel disease - Pathogenetic role and therapeutic implications
32. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms
33. Review article: The mode of action of the aminosalicylates in inflammatory bowel disease
34. Review article: Immunosuppressive therapy for inflammatory bowel disease